welcome to novogen home about us board of directors scientific advisory board management team corporate governance news events research  pipeline gdc cantrixil trilexium collaborations publications  presentations partnering investor centre asx announcements sec filings company reports company meetings corporate presentations analyst reports shareholder services  rights issue options media centre menu home about us overview board of directors scientific advisory board management team corporate governance news events research  pipeline overview gdc cantrixil trilexium test collaborations publications  presentations partnering investor centre overview asx announcements sec filings company reports company meetings corporate presentations analyst reports shareholder services  rights issue options media centre novogen is developing new patientfocused therapies for cancer that have the potential to make a significant impact we aspire to discover and develop new medicines efficiently and effectivelyfor more information visit the ft lexiconlexicon on this pageexplore our toolsalertsdata archiveportfolioworld marketsequities screenerfunds overview  thomson reuters click for restrictions all markets data located on ftcom is subject to the ft terms  conditionsall content on ftcom is for your general information and use only and is not intended to address your particular requirements in particular the content does not constitute any form of advice recommendation representation endorsement or arrangement by ft and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisionsany information that you receive via ftcom is at best delayed intraday data and not real time share price information may be rounded updown and therefore not entirely accurate ft is not responsible for any use of content by you outside its scope as stated in the ft terms  conditions welcome to the ftcom markets data weâ€™re constantly improving and would like to hear from you provide feedback